Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD30 CAR T Cells for Advanced CD30-expressing Lymphomas
NCT03049449Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5F11-28Z CAR T cells in Anaplastic Large Cell Lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma (PTCL) and 5 more, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose. Started Mar 2017; status: completed.
02
Drugs
5F11-28Z CAR T cells
03
Conditions
Anaplastic Large Cell Lymphoma (ALCL)angioimmunoblastic T-cell lymphoma (AITL)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)Primary Mediastinal B-Cell Lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT03049449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049449.